Valneva (NASDAQ:VALN) Shares Gap Down to $7.64

Valneva SE (NASDAQ:VALN - Get Free Report) shares gapped down prior to trading on Monday . The stock had previously closed at $7.64, but opened at $7.46. Valneva shares last traded at $7.49, with a volume of 16,931 shares.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. Guggenheim decreased their price target on shares of Valneva from $18.00 to $17.00 and set a "buy" rating for the company in a research note on Friday, March 22nd. HC Wainwright reaffirmed a "buy" rating and set a $26.00 target price on shares of Valneva in a research note on Thursday, March 21st.

Valneva Stock Performance

The company has a debt-to-equity ratio of 1.04, a current ratio of 1.65 and a quick ratio of 1.37. The business has a 50 day moving average price of $7.64 and a 200 day moving average price of $9.44. The stock has a market capitalization of $535.53 million, a PE ratio of -4.87 and a beta of 2.25.

Valneva (NASDAQ:VALN - Get Free Report) last announced its quarterly earnings results on Wednesday, March 20th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.20 by ($0.70). Valneva had a negative return on equity of 59.48% and a negative net margin of 65.99%. The firm had revenue of $45.12 million during the quarter, compared to the consensus estimate of $45.06 million. As a group, equities research analysts expect that Valneva SE will post 0.11 earnings per share for the current year.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.